Pasticci M.B.; Altissimi M.; Azzara A.; Di Candilo F.; Lapalorcia L.M.; Giustelli G.; Pea F.; Baldelli F., Treatment of post-traumatic hand Staphylococcus aureus osteomyelitis with oral linezolid, «JOURNAL OF CHEMOTHERAPY», 2006, 18, pp. 425 - 429 [articolo]
Pea F.; Poz D.; Viale P.; Pavan F.; Furlanut M., Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2006, 58, pp. 380 - 386 [articolo]
Pea F.; Viale P.; Furlanut M., Antimicrobial therapy in critically ill patients: A review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability, «CLINICAL PHARMACOKINETICS», 2005, 44, pp. 1009 - 1034 [articolo]
Pea F.; Viale P.; Damiani D.; Pavan F.; Cristini F.; Fanin R.; Furlanut M., Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: Helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure, «ANTIMICROBIAL AGENTS AND CHEMOTHERAPY», 2005, 49, pp. 3550 - 3553 [articolo]
Pea F; Mazzei T, Farmaci antifungini, in: Farmacologia – Principi di base e applicazioni terapeutiche, Milano, Edizioni Minerva Medica, 2005, pp. 644 - 652 [commento giuridico]
Furlanut M; Pea F, Farmacocinetica–, in: Farmacologia - Principi di base e applicazioni terapeutiche, Milano, Edizioni Minerva Medica, 2005, pp. 7 - 17 [commento giuridico]
Pea, F, Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions, «CONTRIBUTIONS TO NEPHROLOGY», 2005, 147, pp. 35 - 46 [articolo]
Pea F.; Furlanut M., Levofloxacin PK/PD: From sequential therapy model to high dosage for critical patients, «JOURNAL OF CHEMOTHERAPY», 2004, 16, pp. 8 - 10 [articolo]
Pea F.; Viale P.; Lugano M.; Pavan F.; Scudeller L.; Rocca G.D.; Furlanut M., Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: A report of 2 cases, «AMERICAN JOURNAL OF KIDNEY DISEASES», 2004, 44, pp. 1097 - 1102 [replica/breve intervento]
Pea F.; Viale P.; Candoni A.; Pavan F.; Pagani L.; Damiani D.; Casini M.; Furlanut M., Teicoplanin in patients with acute leukaemia and febrile neutropenia: A special population benefiting from higher dosages, «CLINICAL PHARMACOKINETICS», 2004, 43, pp. 405 - 415 [articolo]
Pea, F; Viale, P; Furlanut, M I, Antimicrobial agents in elective surgery: prophylaxis or "early therapy"?, «JOURNAL OF CHEMOTHERAPY», 2003, 15, pp. 3 - 11 [articolo]
Pea F.; Russo D.; Michieli M.; Damiani D.; Fanin R.; Michelutti A.; Michelutti T.; Piccolrovazzi S.; Baccarani M.; Furlanut M., Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia, «CLINICAL PHARMACOKINETICS», 2003, 42, pp. 851 - 862 [articolo]
Pea F.; Pavan F.; Nascimben E.; Benetton C.; Scotton P.G.; Vaglia A.; Furlanut M., Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy, «ANTIMICROBIAL AGENTS AND CHEMOTHERAPY», 2003, 47, pp. 3104 - 3108 [articolo]
Furlanut M.; Brollo L.; Lugatti E.; Di Qual E.; Dolcet F.; Talmassons G.; Pea F., Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with respiratory tract infections, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2003, 51, pp. 101 - 106 [articolo]
Pea F.; Di Qual E.; Cusenza A.; Brollo L.; Baldassarre M.; Furlanut M., Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia, «CLINICAL PHARMACOKINETICS», 2003, 42, pp. 589 - 598 [articolo]
